ELIGO BIOSCIENCE

Company Overview

Eligo Biosciences is a microbiome therapeutics company founded on research from the Lu Lab (MIT) and the Marraffini Lab (Rockefeller University). Initially incubated at the Institut Pasteur, Paris, the company moved into the biotech cluster Paris Biotech Santé in 2017.

Eligo Bioscience, a pioneer in microbiome gene editing therapy, is developing a highly distinctive pipeline of precision medicines to treat unmet medical needs in oncology, inflammation and autoimmunity that are brought on by our microbiome's expression of particular harmful bacterial genes. Eligo's flagship program, EB003, aims to address a serious unmet medical need by specifically eliminating gut infection.

The technology platform of Eligo Bioscience is based on the development of Eligobiotics, which are engineered phages constructed to deliver antimicrobials targeting selective bacterial populations like MDROs. The proprietary technology used to develop Eligobiotics is known as SSAMS or sequence-specific antimicrobials. These phages are designed to carry specific DNA (deoxyribonucleic acid) directly into targeted bacterial populations in the patient’s GIT. The DNA is optimized to circumvent bacterial defense mechanisms and enable the expression of a CRISPR (clustered regularly interspaced short palindromic repeats)-CAS (CRISPR-associated) system that creates double strand DNA breaks only in antibiotic-resistant genes carried by the targeted bacteria, leaving the other bacterial populations unharmed.

In July 2020, Eligo Bioscience received $1.82 million from CARB-X for the development of a new generation of highly specific antimicrobials to prevent multi-drug-resistant bacterial infections in organ transplant patients.

In Jan. 2021, the advancement of Eligobiotics for the treatment or prevention of acne vulgaris using a ground-breaking CRISPR-based therapy for strain-specific microbiome regulation was the focus of an announcement made by Eligo Bioscience and GlaxoSmithKline. Eligo received an upfront payment and R&D money in accordance with the conditions of the agreement to progress EB005, its discovery program for acne, until preclinical proof of concept.

Company's Business Segments

• Product : GEM technology, FAME technology, SSAM technology, Others
• Services : Licensing, Partnerships, Others